CL2023001367A1 - Inhibidores de btk - Google Patents
Inhibidores de btkInfo
- Publication number
- CL2023001367A1 CL2023001367A1 CL2023001367A CL2023001367A CL2023001367A1 CL 2023001367 A1 CL2023001367 A1 CL 2023001367A1 CL 2023001367 A CL2023001367 A CL 2023001367A CL 2023001367 A CL2023001367 A CL 2023001367A CL 2023001367 A1 CL2023001367 A1 CL 2023001367A1
- Authority
- CL
- Chile
- Prior art keywords
- btk inhibitors
- formula
- btk
- inhibitors
- variables
- Prior art date
Links
- 229940124291 BTK inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provided are compounds of Formula (I’), or pharmaceutically acceptable salts thereof, wherein the variables in the formula are as as defined herein; and methods for their use and production.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063113515P | 2020-11-13 | 2020-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2023001367A1 true CL2023001367A1 (es) | 2024-01-05 |
Family
ID=78828007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2023001367A CL2023001367A1 (es) | 2020-11-13 | 2023-05-11 | Inhibidores de btk |
Country Status (14)
Country | Link |
---|---|
US (1) | US20240083900A1 (es) |
EP (1) | EP4244223A1 (es) |
JP (1) | JP2023549360A (es) |
KR (1) | KR20230119134A (es) |
CN (1) | CN116783199A (es) |
AR (1) | AR124048A1 (es) |
AU (1) | AU2021377891A1 (es) |
BR (1) | BR112023009116A2 (es) |
CL (1) | CL2023001367A1 (es) |
CO (1) | CO2023007677A2 (es) |
MX (1) | MX2023005626A (es) |
TW (1) | TW202233624A (es) |
UY (1) | UY39517A (es) |
WO (1) | WO2022104079A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023086575A1 (en) * | 2021-11-12 | 2023-05-19 | Biogen Ma Inc. | Btk inhibitors |
WO2023220049A1 (en) * | 2022-05-10 | 2023-11-16 | Biogen Ma Inc. | Crystalline polymorphs of n-methyl-n-((1s,3s)-3-methyl-3-((6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide |
WO2024083111A1 (zh) * | 2022-10-18 | 2024-04-25 | 首药控股(北京)股份有限公司 | 一种新型杂环化合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2014118954A (ru) * | 2011-10-12 | 2015-11-20 | Эррэй Биофарма Инк. | 5,7-ЗАМЕЩЕННЫЕ-ИМИДАЗО[1,2-c]ПИРИМИДИНЫ |
KR20160036053A (ko) * | 2013-07-31 | 2016-04-01 | 메르크 파텐트 게엠베하 | Btk 저해제로서 피리딘, 피리미딘, 및 피라진, 및 이들의 용도 |
WO2015157955A1 (en) * | 2014-04-17 | 2015-10-22 | Abbvie Inc. | Heterocyclic btk inhibit ors |
AU2019392232A1 (en) * | 2018-12-07 | 2021-05-20 | Sunshine Lake Pharma Co., Ltd. | RET inhibitors, pharmaceutical compositions and uses thereof |
-
2021
- 2021-11-12 MX MX2023005626A patent/MX2023005626A/es unknown
- 2021-11-12 BR BR112023009116A patent/BR112023009116A2/pt unknown
- 2021-11-12 US US18/036,853 patent/US20240083900A1/en active Pending
- 2021-11-12 AU AU2021377891A patent/AU2021377891A1/en active Pending
- 2021-11-12 JP JP2023528245A patent/JP2023549360A/ja active Pending
- 2021-11-12 TW TW110142205A patent/TW202233624A/zh unknown
- 2021-11-12 KR KR1020237019845A patent/KR20230119134A/ko unknown
- 2021-11-12 AR ARP210103131A patent/AR124048A1/es unknown
- 2021-11-12 CN CN202180089379.6A patent/CN116783199A/zh active Pending
- 2021-11-12 EP EP21823425.0A patent/EP4244223A1/en active Pending
- 2021-11-12 WO PCT/US2021/059168 patent/WO2022104079A1/en active Application Filing
- 2021-11-12 UY UY0001039517A patent/UY39517A/es unknown
-
2023
- 2023-05-11 CL CL2023001367A patent/CL2023001367A1/es unknown
- 2023-06-13 CO CONC2023/0007677A patent/CO2023007677A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2021377891A1 (en) | 2023-07-06 |
AR124048A1 (es) | 2023-02-08 |
CO2023007677A2 (es) | 2023-09-08 |
JP2023549360A (ja) | 2023-11-24 |
CN116783199A (zh) | 2023-09-19 |
AU2021377891A9 (en) | 2024-04-18 |
TW202233624A (zh) | 2022-09-01 |
MX2023005626A (es) | 2023-07-31 |
BR112023009116A2 (pt) | 2023-10-03 |
US20240083900A1 (en) | 2024-03-14 |
EP4244223A1 (en) | 2023-09-20 |
UY39517A (es) | 2022-06-30 |
KR20230119134A (ko) | 2023-08-16 |
WO2022104079A1 (en) | 2022-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2023001367A1 (es) | Inhibidores de btk | |
CY1123186T1 (el) | Μακροκυκλικοι mcl1 αναστολεις για τη θεραπευτικη αντιμετωπιση του καρκινου | |
CY1124837T1 (el) | Ενωσεις βενζο[β]θειοφαινιου ως αγωνιστες sting | |
MD3886991T2 (ro) | Inhibitori KRAS G12C | |
CO2022006858A2 (es) | Inhibidores de pequeñas moléculas de mutante g12c de kras | |
CR20210608A (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
CY1118993T1 (el) | Υποκατεστημενες ενωσεις τετραϋδροϊσοκινολινης ως αναστολεις τελεστη xiα | |
ECSP21091615A (es) | Derivados de benzisoxazol sulfonamida | |
IS2696B (is) | Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð | |
MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
UY28255A1 (es) | Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger | |
CY1109085T1 (el) | Νεα αλατα | |
ECSP099046A (es) | Derivados ciclopropil amina | |
MX2023007287A (es) | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas. | |
MX2019003317A (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
MX2022000164A (es) | Inhibidores de tirosina cinasa no receptora 1 (tnk1) y usos de los mismos. | |
CY1126039T1 (el) | Ενωσεις και συνθεσεις ουριας ως αναστολεις της ατρ-ασης smarca2/brm | |
DE602006009556D1 (de) | Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen | |
MX2023003183A (es) | Compuestos heterociclicos de heteroarilo y usos de los mismos. | |
EA201990766A1 (ru) | Индазольные соединения для применения при повреждениях сухожилий и/или связок | |
BR112022005736A2 (pt) | Compostos de azaindol carboxamida para o tratamento de infecções micobacterianas | |
BR112022005723A2 (pt) | Compostos de indol carboxamida e seu uso para o tratamento de infecções micobacterianas | |
MX2021012499A (es) | Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos. |